{"organizations": [], "uuid": "787c865221622157b0c6ded1820b6ddd72906adb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-synlogic-doses-first-subject-in-ph/brief-synlogic-doses-first-subject-in-phase-1-2a-trial-of-synb1618-for-treatment-of-phenylketonuria-idUSASC09W92", "country": "US", "domain_rank": 408, "title": "BRIEF-Synlogic Doses First Subject In Phase 1/2A Trial Of Synb1618 For Treatment Of Phenylketonuria", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-18T14:09:00.000+03:00", "replies_count": 0, "uuid": "787c865221622157b0c6ded1820b6ddd72906adb"}, "author": "", "url": "https://www.reuters.com/article/brief-synlogic-doses-first-subject-in-ph/brief-synlogic-doses-first-subject-in-phase-1-2a-trial-of-synb1618-for-treatment-of-phenylketonuria-idUSASC09W92", "ord_in_thread": 0, "title": "BRIEF-Synlogic Doses First Subject In Phase 1/2A Trial Of Synb1618 For Treatment Of Phenylketonuria", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "treatment of phenylketonuria", "sentiment": "negative"}, {"name": "synlogic inc", "sentiment": "none"}, {"name": "treatment of phenylketonuria reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 10 AM / Updated 10 minutes ago BRIEF-Synlogic Doses First Subject In Phase 1/2A Trial Of Synb1618 For Treatment Of Phenylketonuria Reuters Staff \nApril 18 (Reuters) - Synlogic Inc: \n* SYNLOGIC DOSES FIRST SUBJECT IN PHASE 1/2A TRIAL OF SYNB1618 FOR TREATMENT OF PHENYLKETONURIA \n* SYNLOGIC INC - SECOND SYNTHETIC BIOTIC PROGRAM TO MOVE INTO CLINICAL STUDIES IN 2018 \n* SYNLOGIC INC - INTERIM DATA FROM SYNB1618 STUDY EXPECTED IN 2018; FULL DATA IN 2019 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-18T14:09:00.000+03:00", "crawled": "2018-04-18T14:34:34.003+03:00", "highlightTitle": ""}